Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity (Q40150549)
Jump to navigation
Jump to search
scientific article published on April 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity |
scientific article published on April 2007 |
Statements
1 reference
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity (English)
1 reference
John C Byrd
1 reference
Michael A Caligiuri
1 reference
Michael R Grever
1 reference
Carolyn M Cheney
1 reference
Thomas S Lin
1 reference
Syed-Rehan A Hussain
1 reference
Amy J Johnson
1 reference
David M Lucas
1 reference
1 April 2007
1 reference
1 reference
13
1 reference
7
1 reference
2144-2150
1 reference
Identifiers
1 reference
1 reference